Transcriptional control of invariant NKT cell development

Immunological Reviews

Volumn 238, Issue 1, 2010, Pages 195-215

  Das, Rupali ^a   Sant'Angelo, Derek B ^b   Nichols, Kim E ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cell fate; Development; Natural killer T cells; Transcription factors

Indexed keywords

CD1D ANTIGEN; EARLY GROWTH RESPONSE FACTOR 2; HIGH MOBILITY GROUP PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN PLZF; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL LINEAGE; CELL MATURATION; CELL SELECTION; CYTOKINE RELEASE; GENETIC TRANSCRIPTION; HUMAN; NATURAL KILLER T CELL; NONHUMAN; ONCOGENE C MYB; ONCOGENE C MYC; ONTOGENY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THYMUS; TRANSCRIPTION REGULATION;

ANTIGENS, CD1D; CELL DIFFERENTIATION; CELL LINEAGE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLYCOLIPIDS; KILLER CELLS, NATURAL; NATURAL KILLER T-CELLS; PROTEIN BINDING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THYMUS GLAND; TRANSCRIPTION FACTORS;

EID: 77958521230     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00962.x     Document Type: Article

References (183)

1. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010;11:197-206.
2. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 2007;7:505-518.
3. Kawano T, et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
4. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-237.
5. + CD1d-dependent precursor stage. J Exp Med 2002;195:835-844.
6. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. Science 2002;296:553-555.
7. Gadue P, Stein PL. NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. J Immunol 2002;169:2397-2406.
8. + T cells lose NK1.1 expression upon in vitro activation. J Immunol 1997;158:5112-5119.
9. - T cells in mice and humans. J Exp Med 1994;180:1097-1106.
10. - T cells. J Exp Med 1994;180:1171-1176.
11. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 1993;178:1-16.
12. - subsets of Valpha24-invariant natural killer T cells in humans. Blood 2004;104:4150-4156.
13. Berzins SP, Cochrane AD, Pellicci DG, Smyth MJ, Godfrey DI. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol 2005;35:1399-1407.
14. Engel I, et al. Co-receptor choice by V alpha14i NKT cells is driven by Th-POK expression rather than avoidance of CD8-mediated negative selection. J Exp Med 2010;207:1015-1029.
15. + NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res 2009;69:7935-7944.
16. Lin H, Nieda M, Nicol AJ. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur J Immunol 2004;34:2664-2671.
17. Lin H, Nieda M, Rozenkov V, Nicol AJ. Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells, and B cells. Exp Hematol 2006;34:289-295.
18. Lin H, Nieda M, Hutton JF, Rozenkov V, Nicol AJ. Comparative gene expression analysis of NKT cell subpopulations. J Leukoc Biol 2006;80:164-173.
19. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000;191:1895-1903.
20. Hammond KJ, et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001;167:1164-1173.
21. Matsuda JL, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000;192:741-754.
22. Marsh RA, et al. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol 2009;132:116-123.
23. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004;199:947-957.
24. Exley MA, et al. Cutting edge: compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol 2002;168:1519-1523.
25. Roy KC, Maricic I, Khurana A, Smith TR, Halder RC, Kumar V. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol 2008;180:2942-2950.
26. Van Rhijn I, et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci USA 2004;101:13578-13583.
27. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008;180:3627-3635.
28. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001;193:893-904.
29. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008;101:277-348.
30. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-336.
31. Akbari O, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582-588.
32. Pillai AB, George TI, Dutt S, Teo P, Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007;178:6242-6251.
33. + NKT cells derived from multiple sclerosis in remission. Int Immunol 2003;15:279-288.
34. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci USA 2007;104:18187-18192.
35. Fuss IJ, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-1497.
36. Duarte N, et al. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 2004;173:3112-3118.
37. Kim JH, Choi EY, Chung DH. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. J Immunol 2007;179:6579-6587.
38. Ambrosino E, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-5136.
39. Treiner E, Lantz O. CD1d- and MR1-restricted invariant T cells: of mice and men. Curr Opin Immunol 2006;18:519-526.
40. + T cells selected by homotypic thymocyte interaction. Immunity 2007;27:763-774.
41. Horai R, et al. Requirements for selection of conventional and innate T lymphocyte lineages. Immunity 2007;27:775-785.
42. + T Cells with Innate Lymphocyte Characteristics. Immunity 2010;33:1-13.
43. + T cells. Nat Immunol 2010;11:709-716.
44. Jordan MS, et al. Complementation in trans of altered thymocyte development in mice expressing mutant forms of the adaptor molecule SLP76. Immunity 2008;28:359-369.
45. Alonzo ES, et al. Development of promyelocytic zinc finger and ThPOK-expressing innate gamma delta T cells is controlled by strength of TCR signaling and Id3. J Immunol 2009;184:1268-1279.
46. + thymocytes. J Immunol 1991;146:1113-1117.
47. + cells. J Immunol 2000;164:2412-2418.
48. + T cells. Int Immunol 1998;10:1491-1499.
49. Benlagha K, Wei DG, Veiga J, Teyton L, Bendelac A. Characterization of the early stages of thymic NKT cell development. J Exp Med 2005;202:485-492.
50. + NK T cells in the early stages of embryogenesis. Proc Natl Acad Sci USA 1996;93:6516-6520.
51. MacDonald HR. Development and selection of NKT cells. Curr Opin Immunol 2002;14:250-254.
52. + T cells. Eur J Immunol 1997;27:1576-1579.
53. Pear WS, Tu L, Stein PL. Lineage choices in the developing thymus: choosing the T and NKT pathways. Curr Opin Immunol 2004;16:167-173.
54. Dao T, et al. Development of CD1d-restricted NKT cells in the mouse thymus. Eur J Immunol 2004;34:3542-3552.
55. + stage of thymic ontogeny. Proc Natl Acad Sci USA 2005;102:5114-5119.
56. Egawa T, et al. Genetic evidence supporting selection of the Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity 2005;22:705-716.
57. Gapin L, Matsuda JL, Surh CD, Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2001;2:971-978.
58. + T cells by CD1-expressing cortical thymocytes. J Exp Med 1995;182:2091-2096.
59. + T cells. J Immunol 2003;171:4105-4112.
60. Schumann J, Pittoni P, Tonti E, Macdonald HR, Dellabona P, Casorati G. Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of Valpha14i NKT cells. J Immunol 2005;175:7303-7310.
61. Elewaut D, et al. The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells. J Exp Med 2003;198:1133-1146.
62. Zhou D, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-1789.
63. Kang SJ, Cresswell P. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat Immunol 2004;5:175-181.
64. Schumann J, Mycko MP, Dellabona P, Casorati G, MacDonald HR. Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol 2006;176:2064-2068.
65. Wei DG, Curran SA, Savage PB, Teyton L, Bendelac A. Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells and consequences for microbial glycolipid recognition. J Exp Med 2006;203:1197-1207.
66. Xia C, et al. Synthesis and biological evaluation of alpha-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3). Bioorg Med Chem Lett 2006;16:2195-2199.
67. Cheng L, et al. Efficient activation of Valpha14 invariant NKT cells by foreign lipid antigen is associated with concurrent dendritic cell-specific self recognition. J Immunol 2007;178:2755-2762.
68. Chiu YH, et al. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat Immunol 2002;3:55-60.
69. Gadola SD, et al. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med 2006;203:2293-2303.
70. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 2007;104:5977-5982.
71. Pellicci DG, et al. Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity 2009;31:47-59.
72. Mallevaey T, et al. T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity 2009;31:60-71.
73. Chun T, et al. CD1d-expressing dendritic cells but not thymic epithelial cells can mediate negative selection of NKT cells. J Exp Med 2003;197:907-918.
74. Pellicci DG, et al. Intrathymic NKT cell development is blocked by the presence of alpha-galactosylceramide. Eur J Immunol 2003;33:1816-1823.
75. Marrella V, et al. A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest 2007;117:1260-1269.
76. + T cell development in CD3 zeta-deficient mice. J Exp Med 1995;182:891-895.
77. Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999;190:1189-1196.
78. Zhang W, et al. Essential role of LAT in T cell development. Immunity 1999;10:323-332.
79. Chan G, Hanke T, Fischer KD. Vav-1 regulates NK T cell development and NK cell cytotoxicity. Eur J Immunol 2001;31:2403-2410.
80. - NK-like cells in the thymus. Blood 2001;97:1765-1775.
81. Felices M, Berg LJ. The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival. J Immunol 2008;180:3007-3018.
82. + thymocytes. Nat Immunol 2002;3:469-476.
83. D'Cruz LM, Knell J, Fujimoto JK, Goldrath AW. An essential role for the transcription factor HEB in thymocyte survival, Tcra rearrangement and the development of natural killer T cells. Nat Immunol 2010;11:240-249.
84. + immature thymocytes for selection into the iNKT lineage. Nat Immunol 2010;11:435-441.
85. Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol 2007;25:337-379.
86. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol 2006;6:56-66.
87. Latour S, et al. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol 2003;5:149-154.
88. Chan B, et al. SAP couples Fyn to SLAM immune receptors. Nat Cell Biol 2003;5:155-160.
89. Nichols KE, et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005;11:340-345.
90. Pasquier B, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005;201:695-701.
91. Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol 2005;174:3153-3157.
92. Nunez-Cruz S, et al. Differential requirement for the SAP-Fyn interaction during NK T cell development and function. J Immunol 2008;181:2311-2320.
93. Griewank K, et al. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 2007;27:751-762.
94. Jordan MA, Fletcher JM, Pellicci D, Baxter AG. Slamf1, the NKT cell control gene Nkt1. J Immunol 2007;178:1618-1627.
95. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001;2:681-690.
96. Wang N, et al. The cell surface receptor SLAM controls T cell and macrophage functions. J Exp Med 2004;199:1255-1264.
97. Alberola-Ila J, Hogquist KA, Swan KA, Bevan MJ, Perlmutter RM. Positive and negative selection invoke distinct signaling pathways. J Exp Med 1996;184:9-18.
98. Cannons JL, et al. SAP regulates T(H)2 differentiation and PKC-theta-mediated activation of NF-kappaB1. Immunity 2004;21:693-706.
99. + regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci USA 2004;101:4566-4571.
100. Stanic AK, Bezbradica JS, Park JJ, Van Kaer L, Boothby MR, Joyce S. Cutting edge: the ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase C theta and NF-kappa B. J Immunol 2004;172:4667-4671.
101. Sivakumar V, Hammond KJ, Howells N, Pfeffer K, Weih F. Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development. J Exp Med 2003;197:1613-1621.
102. Matsuda JL, Zhang Q, Ndonye R, Richardson SK, Howell AR, Gapin L. T-bet concomitantly controls migration, survival, and effector functions during the development of Valpha14i NKT cells. Blood 2006;107:2797-2805.
103. + NKT cells in the thymus. J Immunol 2006;176:4059-4065.
104. Drennan MB, et al. Cutting edge: the chemokine receptor CXCR3 retains invariant NK T cells in the thymus. J Immunol 2009;183:2213-2216.
105. Kovalovsky D, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 2008;9:1055-1064.
106. Savage AK, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008;29:391-403.
107. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997;276:589-592.
108. He X, et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 2005;433:826-833.
109. Sun G, et al. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. Nat Immunol 2005;6:373-381.
110. Maeda T, et al. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 2007;316:860-866.
111. Kovalovsky D, Alonzo ES, Uche OU, Eidson M, Nichols KE, Sant'Angelo DB. PLZF induces the spontaneous acquisition of memory/effector functions in T cells independently of NKT cell-related signals. J Immunol 2010;184:6746-6755.
112. Raberger J, et al. The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells. Proc Natl Acad Sci USA 2008;105:17919-17924.
113. Kreslavsky T, et al. TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci USA 2009;106:12453-12458.
114. + cells are a major component of the gamma delta T cell response to Listeria monocytogenes. J Immunol 1996;156:4280-4289.
115. Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002;2:336-345.
116. Yin Z, Chen C, Szabo SJ, Glimcher LH, Ray A, Craft J. T-Bet expression and failure of GATA-3 cross-regulation lead to default production of IFN-gamma by gammadelta T cells. J Immunol 2002;168:1566-1571.
117. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006;177:4662-4669.
118. Jensen KD, et al. Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity 2008;29:90-100.
119. Gerber DJ, Azuara V, Levraud JP, Huang SY, Lembezat MP, Pereira P. IL-4-producing gamma delta T cells that express a very restricted TCR repertoire are preferentially localized in liver and spleen. J Immunol 1999;163:3076-3082.
120. Azuara V, Levraud JP, Lembezat MP, Pereira P. A novel subset of adult gamma delta thymocytes that secretes a distinct pattern of cytokines and expresses a very restricted T cell receptor repertoire. Eur J Immunol 1997;27:544-553.
121. + T cells via MHC class II-dependent thymocyte-thymocyte interaction is a physiological process in humans. J Exp Med 2010;207:237-246.
122. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-663.
123. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227.
124. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
125. Pomerantz JL, Baltimore D. Two pathways to NF-kappaB. Mol Cell 2002;10:693-695.
126. Kontgen F, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995;9:1965-1977.
127. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995;80:321-330.
128. Doi TS, Takahashi T, Taguchi O, Azuma T, Obata Y. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med 1997;185:953-961.
129. + T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 2003;197:861-874.
130. Elewaut D, et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J Exp Med 2003;197:1623-1633.
131. Stanic AK, et al. NF-kappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 2004;172:2265-2273.
132. + transition as well as IL-15-induced expansion of NKT cells. Eur J Immunol 2008;38:3508-3519.
133. Lee AJ, et al. Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J 2010;29:1600-1612.
134. + invariant NKT cell function and homeostatic survival. J Immunol 2008;180:5448-5456.
135. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005;5:472-484.
136. Lazarevic V, et al. The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells. Nat Immunol 2009;10:306-313.
137. Chen F, Chen D, Rothenberg EV. Specific regulation of fos family transcription factors in thymocytes at two developmental checkpoints. Int Immunol 1999;11:677-688.
138. Rincon M, Flavell RA. Regulation of AP-1 and NFAT transcription factors during thymic selection of T cells. Mol Cell Biol 1996;16:1074-1084.
139. Chen D, Rothenberg EV. Molecular basis for developmental changes in interleukin-2 gene inducibility. Mol Cell Biol 1993;13:228-237.
140. Williams KL, et al. BATF transgenic mice reveal a role for activator protein-1 in NKT cell development. J Immunol 2003;170:2417-2426.
141. Zullo AJ, Benlagha K, Bendelac A, Taparowsky EJ. Sensitivity of NK1.1 negative NKT cells to transgenic BATF defines a role for activator protein-1 in the expansion and maturation of immature NKT cells in the thymus. J Immunol 2007;178:58-66.
142. Lawson VJ, Maurice D, Silk JD, Cerundolo V, Weston K. Aberrant selection and function of invariant NKT cells in the absence of AP-1 transcription factor Fra-2. J Immunol 2009;183:2575-2584.
143. Riera-Sans L, Behrens A. Regulation of alphabeta/gammadelta T cell development by the activator protein 1 transcription factor c-Jun. J Immunol 2007;178:5690-5700.
144. Aliahmad P, et al. TOX provides a link between calcineurin activation and CD8 lineage commitment. J Exp Med 2004;199:1089-1099.
145. Wilkinson B, Chen JY, Han P, Rufner KM, Goularte OD, Kaye J. TOX: an HMG box protein implicated in the regulation of thymocyte selection. Nat Immunol 2002;3:272-280.
146. Aliahmad P, Kaye J. Development of all CD4 T lineages requires nuclear factor TOX. J Exp Med 2008;205:245-256.
147. Singer A, Adoro S, Park JH. Lineage fate and intense debate: myths, models and mechanisms of CD4-versus CD8- lineage choice. Nat Rev Immunol 2008;8:788-801.
148. + T cells. Nat Immunol 2008;9:1122-1130.
149. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol 2002;2:309-322.
150. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-645.
151. Huang CY, Bredemeyer AL, Walker LM, Bassing CH, Sleckman BP. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol 2008;38:342-349.
152. Dose M, et al. c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood 2006;108:2669-2677.
153. + natural killer T cell development depends on c-Myc. Proc Natl Acad Sci USA 2009;106:8641-8646.
154. Mycko MP, et al. Selective requirement for c-Myc at an early stage of V(alpha)14i NKT cell development. J Immunol 2009;182:4641-4648.
155. Bain G, et al. E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 1997;17:4782-4791.
156. Barndt R, Dai MF, Zhuang Y. A novel role for HEB downstream or parallel to the pre-TCR signaling pathway during alpha beta thymopoiesis. J Immunol 1999;163:3331-3343.
157. Barndt RJ, Dai M, Zhuang Y. Functions of E2A-HEB heterodimers in T-cell development revealed by a dominant negative mutation of HEB. Mol Cell Biol 2000;20:6677-6685.
158. Wojciechowski J, Lai A, Kondo M, Zhuang Y. E2A and HEB are required to block thymocyte proliferation prior to pre-TCR expression. J Immunol 2007;178:5717-5726.
159. Allen RD, 3rd. Bender TP, Siu G. Ac-Myb is essential for early T cell development. Genes Dev. 1999; 13:1073-1078.
160. Bender TP, Kremer CS, Kraus M, Buch T, Rajewsky K. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat Immunol 2004;5:721-729.
161. Kim PJ, Pai SY, Brigl M, Besra GS, Gumperz J, Ho IC. GATA-3 regulates the development and function of invariant NKT cells. J Immunol 2006;177:6650-6659.
162. Pai SY, Truitt ML, Ting CN, Leiden JM, Glimcher LH, Ho IC. Critical roles for transcription factor GATA-3 in thymocyte development. Immunity 2003;19:863-875.
163. Hernandez-Hoyos G, Anderson MK, Wang C, Rothenberg EV, Alberola-Ila J. GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity 2003;19:83-94.
164. Germanov E, Veinotte L, Cullen R, Chamberlain E, Butcher EC, Johnston B. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol 2008;181:81-91.
165. + T cells. Proc Natl Acad Sci USA 1998;95:8187-8192.
166. Michel ML, et al. Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci USA 2008;105:19845-19850.
167. - NKT cell population. Proc Natl Acad Sci USA 2008;105:11287-11292.
168. Michel ML, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007;204:995-1001.
169. Matsuda JL, et al. Homeostasis of V alpha 14i NKT cells. Nat Immunol 2002;3:966-974.
170. Ranson T, et al. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc Natl Acad Sci USA 2003;100:2663-2668.
171. + alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad Sci USA 2004;101:7058-7063.
172. + NKT cells patrolling liver sinusoids. PLoS Biol 2005;3:e113.
173. + cells originate from multiple pathways. J Immunol 1999;162:3753-3756.
174. + NKT cells. J Immunol 1999;162:5094-5098.
175. Townsend MJ, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004;20:477-494.
176. Matsuda JL, George TC, Hagman J, Gapin L. Temporal dissection of T-bet functions. J Immunol 2007;178:3457-3465.
177. Kee BL. E and ID proteins branch out. Nat Rev Immunol 2009;9:175-184.
178. Boos MD, Yokota Y, Eberl G, Kee BL. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 2007;204:1119-1130.
179. Yokota Y, et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999;397:702-706.
180. + T cell immunity. Nat Immunol 2006;7:1317-1325.
181. Monticelli LA, et al. Transcriptional regulator Id2 controls survival of hepatic NKT cells. Proc Natl Acad Sci USA 2009;106:19461-19466.
182. D'Cruz LM, Yang CY, Goldrath AW. Transcriptional regulation of NKT cell development and homeostasis. Curr Opin Immunol 2010;22:199-205.
183. Cen O, et al. The adaptor molecule signaling lymphocytic activation molecule-associated protein (SAP) regulates IFN-gamma and IL-4 production in V alpha 14 transgenic NKT cells via effects on GATA-3 and T-bet expression. J Immunol 2009;182:1370-1378.